<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268797</url>
  </required_header>
  <id_info>
    <org_study_id>TMS_negative symptoms</org_study_id>
    <nct_id>NCT04268797</nct_id>
  </id_info>
  <brief_title>TMS in Treatment of Schizophrenia Negative Symptoms</brief_title>
  <official_title>Efficacy and Safety of High-frequency Repetitive Transcranial Magnetic Stimulation With H7-coil in the Treatment of Schizophrenia Negative Symptoms; A Multicenter, Randomized, Sham Controlled, Triple Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sveti Ivan Psychiatric Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sveti Ivan Psychiatric Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: to examine the efficacy and safety of high frequency repetitive
      transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty
      days, augmentative to the standard antipsychotic pharmacotherapy and other treatment of
      negative symptoms in schizophrenia.

      Targeted population: patients diagnosed with schizophrenia, 18-55 years old with predominant
      negative symptoms, stable condition for &gt;3 months and unchanged antipsychotic therapy for &gt;1
      months and no treatment with antidepressants.

      Study design: industry independent, multicenter, prospective randomized sham-controlled,
      two-arms, triple-blind superiority clinical trial with concealed allocation and masked
      independent outcome assessment.

      Primary outcome: adjusted median of differences in total SANS score. Adjustment for age,
      gender, baseline total SANS score, duration of the disorder, and antipsychotic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">June 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted median of differences in total SANS score</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Adjusted median of differences in total SANS score (Andreasen, 1989). We will adjust the medians for age, gender, baseline total SANS score, duration of the disorder, and antipsychotic therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SNS score</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in Self-Evaluation of Negative Symptoms Scale (SNS) (Dollfus, Mach and Morello, 2016)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of BNSS score</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in Brief Negative Symptom Scale (BNSS), (Kirkpatrick et al., 2006)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PANSS negative symptom subscale with items rescaled to 0-6 range</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in PANSS negative symptoms subscale with items rescaled to 0-6 range, (Kay, Fiszbein and Opler, 1987)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CDSS score</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in depressive symptoms measured using Calgary Depression Scale for Schizophrenia (CDSS) (Addington, Addington and Schissel, 1990)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The number of patients self-reported side effects during therapy, confirmed by the medical nurse</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in verbal memory</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in verbal memory using Auditory Verbal Learning Test (AVLT), subtest from Wechsler Memory Scale (Revised)-Verbal-Logical Memory</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in visual memory</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in visual memory using Benton's visual retention test (BVRT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in numeric memory</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in numeric memory using subtest from Wechsler Memory Scale (Revised)-Digit Span</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in visual-spatial abilities and executive function</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in visual-spatial abilities and executive function using TMT (A/B) Trail Making Test, and subtest from Wechsler Intelligence Scale (Revised)-Block Design</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in psihomotor speed</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in psihomotor speed using subtest from Wechsler Intelligence Scale (Revised)-Digit Symbol Substitution Test</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in verbal fluency</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in verbal fluency using FAS Verbal Fluency Test</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in recognition of facial expressions of emotions</measure>
    <time_frame>assessed up to 20 days of treatment</time_frame>
    <description>Change in recognition of facial expressions of emotions using the Penn's Emotion Recognition Task test (ER40)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>HR rTMS H7-coil intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sham control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HR rTMS</intervention_name>
    <description>high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days</description>
    <arm_group_label>HR rTMS H7-coil intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham</intervention_name>
    <description>SHAM HF rTMS coil once daily x 20 days</description>
    <arm_group_label>sham control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmation diagnosis of schizophrenia (ICD-10 F20) using the Mini-International
             Neuropsychiatric Interview (MINI) (Lecrubier et al., 1997; Sheehan et al., 1998),

          2. Age 18-55 years,

          3. Both genders,

          4. PANSS negative symptoms subscale score &gt;24,

          5. PANSS positive symptoms subscale score &lt;20,

          6. Stable condition (no acute psychosis exacerbation, no psychiatric hospitalization
             because of relapse or worsening of symptoms) during at least three months,

          7. Stable antipsychotic therapy with no change of drugs or doses during the one months
             before the enrollment.

        Exclusion Criteria:

          1. Antipsychotics dose change or change of antipsychotic drug,

          2. Hospitalization for somatic illness in another institution,

          3. Termination of treatment in a Psychiatric Hospital &quot;Sveti Ivan&quot;,

          4. Pregnancy,

          5. Missed more than three consecutive interventions,

          6. Withdrawal of consent to participate for the sake of intolerance of TMS or for other
             reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PB Sveti Ivan</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ena Ivezic, MA</last_name>
      <phone>38513430171</phone>
      <email>ena.ivezic@pbsvi.hr</email>
    </contact>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

